Corporate$BIIB8:34 AM ET

JPMorgan Upgrades Biogen to Overweight, Cites Pipeline Data Readouts

By BORSA NewsroomPublished Oct 12, 2026, 8:34 AM EDTUpdated Oct 12, 2026, 8:35 AM EDT

JPMorgan upgraded Biogen to overweight from neutral. Analysts see a promising path with key data next year for felzartamab and litifilimab. Biogen is up 3.6% premarket.

Sentimentbullish 70

Bullish · 70 of 100

Impact60

medium · sector-wide

Confidence80%

high confidence · single wire

Eventdeveloping

v1 · alerted to followers

WHAT WE KNOW

JPMorgan upgraded Biogen to overweight from neutral.